Structure Therapeutics (NASDAQ:GPCR) Now Covered by William Blair

William Blair began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a report published on Friday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the stock.

Several other brokerages have also weighed in on GPCR. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities reissued a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Stock Up 4.1 %

Shares of NASDAQ GPCR opened at $23.75 on Friday. The business’s 50 day moving average is $26.58 and its two-hundred day moving average is $33.59. The company has a market cap of $1.36 billion, a P/E ratio of -32.09 and a beta of -2.75. Structure Therapeutics has a 12 month low of $19.61 and a 12 month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sell-side analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Spire Wealth Management acquired a new position in Structure Therapeutics in the fourth quarter worth $243,000. JPMorgan Chase & Co. boosted its stake in Structure Therapeutics by 302.3% in the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock worth $1,489,000 after purchasing an additional 25,500 shares in the last quarter. Vestal Point Capital LP boosted its stake in Structure Therapeutics by 105.4% in the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares in the last quarter. abrdn plc boosted its stake in Structure Therapeutics by 132.7% in the third quarter. abrdn plc now owns 217,083 shares of the company’s stock worth $9,528,000 after purchasing an additional 123,789 shares in the last quarter. Finally, Barclays PLC boosted its stake in Structure Therapeutics by 64.5% in the third quarter. Barclays PLC now owns 81,138 shares of the company’s stock worth $3,562,000 after purchasing an additional 31,815 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.